Skip to main content
. 2017 Dec 14;118(3):388–397. doi: 10.1038/bjc.2017.432

Figure 3.

Figure 3

The FP/ABT-199 regimen circumvents various forms of MM-related drug- and microenvironment-related resistance. (A) U266 or PS-R cells were incubated with 500 nM ABT-199±100 nM FP or 10 nM bortezomib (btz) for 24 h, followed by flow cytometry after staining with 7-AAD; (B) 8226 or 8266 cells resistant to bortezomib (V10R), revlimid (R10R), or melphalin (LR5) were treated with 500 nM ABT-199±100 nM FP for 24 h. Cell death was then determined by flow cytometry after staining with 7-AAD; (C) Luciferase-labelled U266 (upper panel) or PS-R (lower panel) cells co-cultured±BM stromal HS-5 cells were incubated with 750 nM ABT-199+100 nM FP or 10 nM bortezomib for 24 h. Cell viability was determined by bioluminescence assay; (D) GFP-labelled U266 (upper panel) or PS-R (lower panel) cells co-cultured±BM stromal HS-5 cells were treated with 750 nM ABT-199±100 nM FP for 24 h. Cells were stained with 7-AAD to monitor MM (GFP+) cell death (× 200 magnification). Veh, vehicle; BF, bright field. P-values indicate no significant difference between groups. The results are representative of three separate experiments. A full colour version of this figure is available at the British Journal of Cancer journal online.